rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Apollomics Inc. - Class A

APLM · Nasdaq

Health CareBiotechnologyIn trend

APLM stood above a rising 150-day average in 34 of the last 52 weekly readings, including each of the last 8 weeks. It is 18.5% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
8 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$16.5M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
4 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$15.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Hung-Wen ChenChief Executive Officerbought166,667at $12.0014 Aug 2026filed 17 Aug 2026
Hung-Wen ChenChief Executive Officerbought103,333at $15.0014 Aug 2026filed 17 Aug 2026
Hung-Wen ChenChief Executive Officerbought266,667at $15.0014 Aug 2026filed 17 Aug 2026
Peter Kuan-How LinChief Financial Officerbought26,667at $15.0014 Aug 2026filed 17 Aug 2026
Yi-Kuei ChenChief Operating Officerbought20,000at $15.0014 Aug 2026filed 17 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders4+0 on the quarter
New · exited1 · 1
Reported value$224K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCnew · filed 14 Aug 202610,664$224K+10,664
SBI Securities Co., Ltd.unchanged · filed 23 Jul 20269$18900.0%
UBS Group AGreduced · filed 13 Aug 20262$42-140−98.6%
BlackRock, Inc.unchanged · filed 7 Aug 20261$2100.0%
31 Mar 2023 – 30 Jun 2026
4812Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Hong-Jung Chen Company insiderDirector · last 15 Sep 20260 · 0
Hsien-Shu Tsai Company insiderDirector · last 15 Sep 20260 · 0
Hung Hsien Yen Company insiderDirector · last 15 Sep 20260 · 0
Hung-Wen Chen Company insiderChief Executive Officer · last 15 Sep 20261 · 0
Peter Kuan-How Lin Company insiderChief Financial Officer · last 15 Sep 20261 · 0
Yi-Kuei Chen Company insiderChief Operating Officer · last 15 Sep 20261 · 0
Ya-Chi Huang Company insiderDirector · last 14 Sep 20260 · 0
Chen-Huan Jan Company insiderDirector · last 15 Jun 20260 · 0
Yi-An Chu Company insiderDirector · last 15 Jun 20260 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 24 Apr 202699.0%

Analyst forecasts

No analyst forecasts yet.